The story of Viagra, initially marketed by copyright, presents a intricate case study for investors considering the drug arena . Despite its early success and generation of vast in earnings , the patent lapse has opened the floodgates for generic medications, substantially eroding profit opportunities. This shift raises doubts about the long-term v